Relmada Therapeutics (RLMD) Shares Outstanding (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Shares Outstanding data on file, last reported at $104.9 million in Q1 2026.

• Quarterly Shares Outstanding rose 216.01% year-over-year to $104.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.9 million (up 216.01% YoY) and the FY2025 annual result came in at $73.3 million, up 143.03% from the prior year.
• Shares Outstanding advanced to $104.9 million in Q1 2026 per RLMD's latest filing, from $73.3 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $104.9 million in Q1 2026 and bottomed at $28.6 million in Q3 2022.
• The 5-year median for Shares Outstanding is $30.2 million (2024), against an average of $37.5 million.
• The widest annual swing landed in 2023, when Shares Outstanding changed 0.0%; it then soared 216.01% in 2026.
• Tracing RLMD's Shares Outstanding over 5 years: stood at $30.1 million in 2022, then changed by 0.0% to $30.1 million in 2023, then climbed by 0.25% to $30.2 million in 2024, then soared by 143.03% to $73.3 million in 2025, then surged by 43.03% to $104.9 million in 2026.
• Per Business Quant, the three latest RLMD Shares Outstanding figures stand at $104.9 million (Q1 2026), $73.3 million (Q4 2025), and $33.2 million (Q3 2025).

Peer Comparison